Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Fixed-Duration Therapy for Relapsed CLL

January 28th 2020

Health Maintenance in CLL

January 28th 2020

Distinguishing Features Among BTK Inhibitors

January 28th 2020

Combining Targeted Therapies in CLL

January 28th 2020

Ibrutinib + Venetoclax for CLL

January 28th 2020

Treatment for Younger Fit Patients With CLL

January 28th 2020

The Role of Venetoclax + Rituximab in CLL

January 28th 2020

Acalabrutinib, Second-Generation BTK Inhibitor for CLL

January 28th 2020

Long-Term Experience With BTK Inhibitors for CLL

January 28th 2020

Chemoimmunotherapy for CLL; Still a Role?

January 28th 2020

Mutation Status Throughout the CLL Clinical Course

January 28th 2020

Prognostic Factors in Patients With CLL

January 28th 2020

Precision Medicine Becomes More Widespread in Breast Cancer

January 27th 2020

Francisco J. Esteva, MD, PhD, discusses how the use of precision medicine has helped improve the treatment of patients with breast cancer.

Dr. Cheng on Molecular Testing Considerations in Prostate Cancer

January 25th 2020

Heather H. Cheng, MD, PhD, discusses considerations for molecular testing in prostate cancer.

Dr. Tolaney on the Advantages of ctDNA Versus Tissue Biopsy in Breast Cancer

January 25th 2020

Sara M. Tolaney, MD, MPH, discusses the advantages of circulating tumor DNA versus tissue biopsy in breast cancer.

Dr. Chittoor on Targetable Mutations and Respective Treatments in NSCLC

January 24th 2020

Sreeni Chittoor, MD, FACP, discusses targetable mutations and respective treatment options for patients with metastatic non–small cell lung cancer.

Dr. Levy on Positive and Negative Biomarkers for Immunotherapy in Lung Cancer

January 24th 2020

Benjamin P. Levy, MD, discusses biomarkers for immunotherapy in lung cancer.

Dr. Gibbs on Testing for p16 and p21 in Osteosarcoma

January 23rd 2020

C. Parker Gibbs Jr, MD, discusses how to test for p16 and p21 in patients with osteosarcoma.

Blood-Based Assay Identifies Hard-to-Detect Gastrointestinal Cancers

January 22nd 2020

A DNA methylation-based cell-free DNA assay demonstrated high specificity and accurate localization of cancers to specific regions of the gastrointestinal tract.

Dr. Norden on Cost and Effectiveness of Genomic Testing

January 22nd 2020

Andrew Norden, MD, MPH, MBA, chief medical officer, Cota, discusses concerns surrounding cost and efficacy of molecular testing.